Narayana Hrudayalaya Ltd. ( ($IN:NH) ) just unveiled an update. Narayana Hrudayalaya Ltd. has incorporated a new wholly owned subsidiary, Narayana ...

In this briefing: ORMP: Advancing Clinical Activities RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader 1. ORMP: Advancing Clinical Activities ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments. The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid. 2. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need.

In this briefing: RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer 1. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need. Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies. 2. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.

In this briefing: WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects! 1. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs. Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.

Narayana Hrudayalaya shares saw a significant jump following strong quarterly results. The healthcare chain reported robust growth in revenue and profit for the September quarter. Both Indian and Cayman Islands operations contributed to this impressive performance. The company's net profit and operating revenue increased substantially year-on-year. This positive financial update has boosted investor confidence.

Narayana Hrudayalaya's share price rose over 7% after reporting record revenue and profitability for Q2FY26, with a net profit surge of 29.6% to ₹258 crore. Consolidated operating revenue increased by 20.3% to ₹1643.8 crore, driven by strong performance in both India and Cayman businesses.

The CGHS revamp addresses long-standing concerns from private hospitals that earlier packages were outdated and failed to reflect rising medical costs

The stock has surged nearly 65% in 2025, but the analyst highlights a buildup of risk factors that could trigger a near-term correction.

Healthcare company Narayana Hrudayalaya Limited has … to documents accessed by Propstack. Healthcare company Narayana Hrudayalaya Limited has … along Bannerghatta Road, a prominent healthcare and residential corridor in south …